To: [redacted] 5.1.2e [redacted] 5.1.2e @rivm.nl]
From: [redacted] 5.1.2e [redacted]
Sent: Tue 11/17/2020 2:46:06 PM
Subject: FW: Latebreaker abstract for ESWI: association between influenza vaccination and COVID-19
Received: Tue 11/17/2020 2:46:07 PM
I-MOVE-COVID-19 primary care ESWI abstract flu vaccine and COVID-19 association v2.1.docx

Dit is het abstract waar ik het over had

Groet
5.1.2e

-----Original Message-----
From: [redacted] 5.1.2e [redacted] 5.1.2e @epiconcept.fr>
Sent: vrijdag 13 november 2020 11:00
To: [redacted] 5.1.2e [redacted] 5.1.2e @rivm.nl>
Cc: [redacted] 5.1.2e [redacted] 5.1.2e @nivel.nl) < [redacted] 5.1.2e @nivel.nl>; [redacted] 5.1.2e [redacted] < [redacted] 5.1.2e @rivm.nl>; [redacted] 5.1.2e
< [redacted] 5.1.2e @rivm.nl>; [redacted] 5.1.2e [redacted] < [redacted] 5.1.2e @rivm.nl>
Subject: Re: Latebreaker abstract for ESWI: association between influenza vaccination and COVID-19

Dear RIVM and Nivel colleagues,

Many thanks again for your very useful and important comments on the ESWI abstract.

We included the vast majority of your comments in the revised abstract (attached), including your comments on the title and the introduction.

In the methods, we included most of your comments, except

- We did not mention the swabbing type (nose and/or throat). While this is important, we had to omit due to word count

[redacted] 5.1.2i Wetenschappelijk beraad

In the discussion section we tried to include as many of your comments as possible, but we were hampered also by the word count (we are at the limit).

We hope the abstract as it is now is acceptable to you.

And many thanks for your comments, they have made the abstract much better.

Wishing you all the best,

5.1.2e

On 11/11/2020 16:18, [redacted] 5.1.2e [redacted] wrote:
> Dear [redacted] 5.1.2e [redacted],
>
> Please find attached our comments and suggestions.
>
> Best regards,
>
> [redacted] 5.1.2e [redacted]

>
> -----Original Message-----
> From: 5.1.2e < 5.1.2e @epiconcept.fr>
> Sent: donderdag 5 november 2020 09:38
> To: 5.1.2e @nivel.nl; 5.1.2e
> < 5.1.2e @phe.gov.uk>; 5.1.2e
> < 5.1.2e @phe.gov.uk>; 5.1.2e @iplesp.upmc.fr; 5.1.2e
> 5.1.2e < 5.1.2e @aphp.fr>; 5.1.2e
> < 5.1.2e @iplesp.upmc.fr>; 5.1.2e
> < 5.1.2e @univ-corse.fr>; 5.1.2e @isciii.es; 5.1.2e @isciii.es;
> 5.1.2e @isciii.es; 5.1.2e < 5.1.2e @isciii.es>;
> 5.1.2e @navarra.es; 5.1.2e < 5.1.2e @rivm.nl>;
> 5.1.2e < 5.1.2e @rivm.nl>; 5.1.2e @hse.ie;
> 5.1.2e @hse.ie; 5.1.2e < 5.1.2e @nhs.net>; 5.1.2e ,
> 5.1.2e (NHS FIFE) < 5.1.2e @nhs.net>; 5.1.2e (NHS
> NATIONAL SERVICES SCOTLAND)' < 5.1.2e @nhs.scot>; 5.1.2e
> 5.1.2e < 5.1.2e @strath.ac.uk>;
> 5.1.2e @insa.min-saude.pt; 5.1.2e
> < 5.1.2e @insa.min-saude.pt>; 5.1.2e @insa.min-saude.pt;
> 5.1.2e @insa.min-saude.pt; 5.1.2e @insa.min-saude.pt;
> 5.1.2e < 5.1.2e @dgs.min-saude.pt>;
> 5.1.2e @folkhalsomyndigheten.se;
> 5.1.2e @folkhalsomyndigheten.se;
> 5.1.2e @pasteur.fr; 5.1.2e @pasteur.fr; 5.1.2e
> 5.1.2e < 5.1.2e @phc.ox.ac.uk>; 5.1.2e
> < 5.1.2e @phc.ox.ac.uk>; 5.1.2e
> < 5.1.2e @phc.ox.ac.uk>; 5.1.2e (PUBLIC HEALTH
> SCOTLAND) < 5.1.2e @nhs.scot>; 5.1.2e PUBLIC HEALTH
> SCOTLAND) < 5.1.2e @nhs.net>; 5.1.2e < 5.1.2e @ucd.ie>;
> 5.1.2e @ucd.ie; 5.1.2e < 5.1.2e @nivel.nl>;
> 5.1.2e @epiconcept.fr; 5.1.2e @navarra.es;
> 5.1.2e @navarra.es; 5.1.2e @nhs.scot; 5.1.2e
> 5.1.2e < 5.1.2e @rivm.nl>; 5.1.2e
> 5.1.2e < 5.1.2e @dgs.min-saude.pt>
> Cc: 5.1.2e @epiconcept.fr; 5.1.2e @ec.europa.eu;
> 5.1.2e < 5.1.2e @who.int>; 5.1.2e
> < 5.1.2e @ecdc.europa.eu>; 5.1.2e @ecdc.europa.eu;
> 5.1.2e < 5.1.2e @ecdc.europa.eu>
> Subject: Latebreaker abstract for ESWI: association between influenza
> vaccination and COVID-19
>
> Dear all,
>
> As discussed during the recent primary care WP2/WP4 meeting, please find attached our latebreaker abstract on the association between influenza vaccination and COVID-19, for the ESWI conference.
>
> The word count is generous luckily (it's quite a long abstract).
>

5.1.2a

>

5.1.2a

>
> Could you have a look through the abstract and let us know if you have any comments/suggestions? And could you let us know which authors to include? Could you do this by Thursday the 12th of November? Apologies for this short deadline, we need to submit on the 15th.
>
> We did lots of additional analyses, so please do not hesitate to contact us if you have questions on methods or on further results. Hopefully we can share soon with you a draft manuscript that will outline all of this.
>
> Wishing you all the best and with thanks,
>
> 5.1.2e

>
>
> Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
> www.rivm.nl<http://www.rivm.nl/> De zorg voor morgen begint vandaag
>
> This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
> www.rivm.nl/en<http://www.rivm.nl/en> Committed to health and
> sustainability